香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 成立合資公司之 自願公告 深圳金麗醫療美容門診部於二零一四年在深圳成立，提供五個類別的醫療美容服 務，擁有超過30,000名客戶會員。 本公告由中基長壽科學集團有限公司（「本公司」）自願作出。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二四年十一月七日（交易時間 後），本公司之全資附屬公司深圳市中基健康科學有限公司（「中基健康」）與深圳美 洛斯醫療美容投資有限公司（「美洛斯醫療」）及深圳金麗醫療美容門診部簽訂有關於 中華人民共和國（「中國」）成立一間合資公司（「合資公司」）之合資協議（「合資協 議」），合資公司於成立時將由中基健康擁有51%及美洛斯醫療擁有49%的股權。合 資公司將主要從事於中國提供長壽健康服務。 合資公司的初始註 ...

Dividend and Financial Performance - The Company has not declared an interim dividend for the six months ended June 30, 2024, consistent with the previous year[5]. - For HY2024, the Group recorded total revenue of HK$42,403,000, an increase from HK$29,911,000 in HY2023[26]. - The Group reported a loss of HK$917,000 for HY2024, compared to a profit of HK$1,938,000 in HY2023[26]. - As of June 30, 2024, the basic and diluted loss per share was HK$0.2 cents, compared to earnings of HK$0.01 cents per share on June 30, 2023[27]. - The Group's consolidated net assets were HK$432,113,000 as of June 30, 2024, slightly up from HK$430,465,000 on December 31, 2023[27]. - The Company reported a total comprehensive loss for the period of HK$17,937,000 for the six months ended June 30, 2024, compared to a total comprehensive loss of HK$78,683,000 for the same period in 2023[180]. Business Operations and Strategy - The Company is focusing on expanding its longevity science business while managing existing operations in money lending, financial advisory, securities, and property investment[6]. - The money lending and financial advisory business has been restructured to comply with new PRC guidelines, transitioning to a non-P2P model[8]. - The focus on longevity science is part of a broader strategy to diversify and strengthen the Company's market position[6]. - The Company continues to adapt to regulatory changes in the PRC financial landscape, ensuring its business model aligns with current guidelines[8]. - The Group is focusing on enhancing its longevity science business through membership and distribution channels, indicating a commitment to future growth[26]. Regulatory Compliance and Restructuring - The PRC subsidiary, Tian Xing, has normalized its operations and restored its status with regulatory departments, including the Beijing Commerce Department and the Beijing Taxation Bureau[8]. - The Company has successfully regained possession of all necessary company chops and seals for its PRC subsidiary during 2023[8]. - The restructuring of the money lending business follows the cessation of the Caijia Peer-to-Peer Internet Credit Youtoubao loan platform due to regulatory changes[7]. - The Company has hired new staff and disassociated from all former managerial personnel in Tian Xing to ensure compliance and operational integrity[8]. - The Company is committed to maintaining compliance with evolving regulations in the financial sector to safeguard its operations and reputation[8]. Revenue and Segment Performance - The longevity science business generated revenue of approximately HK$25,180,000 for HY2024, compared to HK$11,868,000 in HY2023[28]. - Revenue from diagnostic consultation and medical testing was approximately HK$21,700,000, while sales of longevity biological products contributed approximately HK$3,480,000[28]. - The money lending and financial advisory business maintained static revenue of HK$17,223,000 with a segment profit of HK$16,233,000 for HY2024[26]. - The segment loss for the longevity science business was approximately HK$4,342,000 for HY2024, an improvement from HK$13,283,000 in HY2023[28]. - Loan interest income for the period was HK$17,223,000, slightly down from HK$18,043,000 in 2023, reflecting a decrease of approximately 4.5%[192]. Cash Flow and Financial Position - Cash and bank balances were approximately HK$78,705,000 as of June 30, 2024, down from HK$81,075,000 as of December 31, 2023[86]. - The Group recorded net current assets of approximately HK$255,761,000 as of June 30, 2024, compared to HK$250,127,000 as of December 31, 2023[86]. - Net cash used in operating activities was HK$16,000 for the six months ended June 30, 2024, a significant improvement from HK$15,849,000 in the prior year[183]. - Cash flows from investing activities generated a net cash inflow of HK$2,089,000 for the six months ended June 30, 2024, compared to HK$12,000 in the same period of 2023[183]. - The net increase in cash and cash equivalents for the period was HK$20,921,000, compared to a decrease of HK$6,026,000 in the same period last year[184]. Share Capital and Options - The total number of issued ordinary shares increased to 546,529,549 as of June 30, 2024, from 455,441,291 as of December 31, 2023[90]. - The Company issued an additional 91,088,258 shares during HY2024[90]. - As of June 30, 2024, the number of share options available for grant under the 2022 Share Option Scheme was 38,701,026 shares[114]. - No share options were granted under the 2022 Share Option Scheme for HY2024, resulting in no outstanding share options as of June 30, 2024[120][123]. - The maximum entitlement for each participant under the 2022 Share Option Scheme is limited to 1% of the total number of shares of the Company in issue at the date of grant within any 12-month period[121][124]. Environmental and Corporate Governance - The company is committed to environmental sustainability and will issue its environmental, social, and governance report for the year ending December 31, 2024, in the next annual report[170]. - The Company has complied with the Corporate Governance Code during HY2024[158]. - All existing Directors confirmed compliance with the Model Code for Security Transactions during HY2024[161].

Financial Performance - The group's revenue increased by 41.8% to HKD 42.4 million in the first half of 2024, compared to HKD 29.9 million in the same period of 2023[2] - Gross profit rose by 25.6% to HKD 33.3 million in the first half of 2024, up from HKD 26.5 million in the first half of 2023[2] - Profit before tax decreased by 85.9% to HKD 0.7 million in the first half of 2024, down from HKD 5.3 million in the same period of 2023[2] - The group reported a loss attributable to owners of the company of HKD 1.021 million in the first half of 2024, compared to a profit of HKD 1.782 million in the same period of 2023[3] - Total comprehensive loss for the period amounted to HKD 17.937 million in the first half of 2024, compared to a loss of HKD 78.683 million in the same period of 2023[4] - The company reported a loss of HKD 917,000 in the first half of 2024, compared to a profit of HKD 1,938,000 in the same period of 2023[57] Assets and Liabilities - As of June 30, 2024, the group's net assets increased by 0.4% to HKD 432.1 million, compared to HKD 430.5 million on December 31, 2023[2] - The group's total assets less current liabilities stood at HKD 434.1 million as of June 30, 2024, compared to HKD 435.9 million on December 31, 2023[5] - Non-current assets totaled HKD 178.4 million as of June 30, 2024, down from HKD 185.8 million on December 31, 2023[5] - Current assets amounted to HKD 320.5 million as of June 30, 2024, compared to HKD 323.5 million on December 31, 2023[5] - The group's total liabilities for the reportable segments were HKD 31,573,000 as of June 30, 2024, compared to HKD 40,300,000 as of June 30, 2023[16] Revenue Segments - Revenue from the health and medical products segment was HKD 3,480,000, up from HKD 2,351,000, while revenue from diagnostic and medical testing services surged to HKD 21,700,000 from HKD 9,517,000[12] - The company’s external customer revenue from the Hong Kong market was HKD 9,817,000 for the six months ended June 30, 2024, compared to HKD 2,313,000 in the same period of 2023[18] - External customer revenue from mainland China reached HKD 32,586,000, an increase from HKD 27,598,000 in the same period of 2023[18] - The longevity science segment generated revenue of approximately HKD 25,180,000 in the first half of 2024, up from HKD 11,868,000 in the same period of 2023, indicating a growth of about 112%[59] Dividends and Share Issuance - The group did not recommend an interim dividend for the first half of 2024, consistent with the same period in 2023[2] - The company issued a total of 91,088,258 new shares on June 6, 2024, raising a net amount of approximately HKD 19.4 million, with 60% allocated to expanding its longevity science business and new biopharmaceutical product trade[86] - The company raised approximately HKD 14,016,352 from the issuance of 297,300,000 shares at a price of HKD 0.049 per share in May 2023[46] Operational Developments - The company has restructured its internal reporting framework, merging the lending and financial consulting segments into a single division[14] - The company has enhanced its R&D capabilities by recruiting international biotech experts, including a Nobel Prize laureate, to strengthen its strategic goals[61] - The company is developing and producing flagship longevity biological products, including NMN and VC sustained-release tablets, with all products receiving top global safety certifications[62] - The company plans to establish a "Internet + Healthcare" longevity system platform, leveraging its existing customer base and market network[62] Legal and Compliance - The company has extended its legal recovery service agreement with Dongwei Law Firm until August 2025 to enhance loan recovery efforts[52] - The company reported no significant contingent liabilities or capital commitments as of June 30, 2024[48][49] - The audit committee has reviewed and approved the consolidated financial statements for the first half of 2024, ensuring compliance with applicable accounting standards and regulations[87] Market Conditions and Future Outlook - Management is optimistic about the growth of the longevity science business, which is expected to support revenue growth, particularly through a network of 2,000 retail pharmacies in China[64] - The group continues to monitor the market for suitable tenants to generate stable rental income from its property investments, which currently do not yield any revenue[68] - The group is actively exploring opportunities for its lending business amid reduced loan demand from Hong Kong clients due to high interest rates and the impact of the COVID-19 pandemic[65]

Financial Performance - In 2023, the revenue of Zhong Ji Longevity Science Group was HK$64,989,000, a decrease of 27.5% compared to HK$89,668,000 in 2022[13]. - The profit attributable to the owners of the Company for 2023 was HK$2,313,000, recovering from a loss of HK$904,000 in 2022[13]. - For FY2023, the Group recorded total revenue of approximately HK$64,989,000, a decrease of 27.5% from HK$89,668,000 in FY2022[45]. - The profit for FY2023 amounted to approximately HK$2,523,000, compared to a profit of HK$701,000 in FY2022[45]. - The longevity science business generated revenue of approximately HK$31,326,000, down from HK$43,920,000 in FY2022, resulting in a segment loss of approximately HK$24,016,000[48]. - Revenue from diagnostic consultation and medical testing was approximately HK$26,879,000, showing stability compared to HK$26,370,000 in FY2022[53]. - Revenue from the sales of longevity biological products decreased to approximately HK$4,447,000 from HK$17,550,000 in FY2022 due to customs clearance delays[52]. - The money lending and financial advisory business recorded segment revenue of approximately HK$33,663,000, down from HK$45,748,000 in FY2022, with a segment profit of approximately HK$25,354,000[56]. - The Group's consolidated net assets as of December 31, 2023, were approximately HK$430,465,000, an increase from HK$420,849,000 in FY2022[46]. - Basic and diluted earnings per share for FY2023 were approximately HK$0.15, compared to a loss per share of HK$0.06 in FY2022[46]. Strategic Goals and Expansion - The Company aims to achieve a leading position in global sales revenue of lipid-lowering biological products by 2024[20]. - The "ZJ1 VC sustained-release tablet" product is now available for sale to over 50 million consumers in 117 countries[20]. - The Company is committed to establishing a world-leading longevity science transformation and application platform[18]. - The strategy includes expansion through joint ventures, mergers, and acquisitions, focusing on brand building and industry-finance integration[18]. - The Group aims to achieve global leadership in the sales revenue of lipid-lowering biological products by 2024, with the competitive product ZJ1 VC sustained in over 117 countries for more than 50 million users[22]. - The Company is expanding its longevity management services in 26 major cities worldwide, enhancing its brand image as a preferred platform for high net-worth individuals[24][28]. - The Group plans to focus on the development and expansion of its longevity science business, which is expected to drive future revenue growth[55]. Operational Efficiency and Quality - The Company is focusing on enhancing operational efficiency and quality while refining its industry and product chains[19]. - The Group's strategic focus includes improving operational quality and efficiency in the longevity management field, amidst a challenging economic environment[25][29]. - The Group's financial performance is being enhanced through diversification into promising longevity medical health businesses[30][41]. - Increased marketing, advertising, and promotion expenses for the longevity science business amounted to approximately HK$19,105,000 during FY2023[48]. - The Group aims to operate under a light asset model to reduce operational pressure and risk while expanding its longevity science business[162]. Investment and Financial Position - Investment properties increased to HK$25,295,000 in 2023 from HK$24,411,000 in 2022, reflecting a growth of 3.2%[16]. - The total shareholders' equity as of December 31, 2023, was HK$430,465,000, up from HK$420,849,000 in 2022, indicating a growth of 1.5%[16]. - The Group's fair value of equity securities listed on the Stock Exchange decreased to approximately HK$5,847,000 as of 31 December 2023, down from HK$9,859,000 as of 31 December 2022[61]. - The Independent Recovery Committee successfully recovered HK$30,000,000 from a borrower entity, negotiating the recovery of previously impaired loans totaling approximately HK$1,076,000,000[60]. - The Group's gearing ratio as of December 31, 2023, was approximately 1.6%, unchanged from December 31, 2022[148]. - The Group did not pledge any assets to banks or other financial institutions as of December 31, 2023, nor did it have any corporate guarantees[146]. Management and Governance - The executive team includes Mr. Yan Li, who has over 8 years of experience in advanced medical and biological technology management, and Mr. Yan Yifan, who has been with the company since April 2022[174][175]. - The management team has extensive experience in corporate management and business operations, with members holding significant positions in various organizations[179][180]. - The board includes non-executive directors with significant experience in innovation and investment consulting, enhancing the company's strategic direction[184][185]. - The company emphasizes the importance of risk management and has established several committees to oversee this aspect[188]. - The board includes members with significant experience in auditing, accounting, and financial management, enhancing the company's governance structure[188]. - The company aims to strengthen its market position through strategic appointments and governance improvements[189]. Loan and Borrower Management - The Group manages over 14 corporate and personal borrower loans, with principal sizes ranging from approximately HK$47.9 million for personal borrowers to HK$64.4 million for corporate loans[109]. - As of December 31, 2023, the corporate and personal borrowers business loan assets were approximately HK$819,455,000 before impairments, slightly up from HK$819,403,000 in 2022[113]. - The net carrying value of these loan assets was approximately HK$177,732,000, an increase from HK$172,289,000 in the previous year[113]. - The top five borrowers accounted for approximately 79.93% of the total loan and interest receivables of the Group as of December 31, 2023, consistent with the previous year[113]. - The loan leverage ratio for collateralized loans ranged from 31.79% to 74.69%, secured by properties, financial assets, and dividend rights[113]. - The Group has initiated recovery actions on previously impaired loans, indicating a proactive approach to asset management[113]. Shareholder and Capital Management - The total number of issued shares of the Company increased from 4,257,112,915 shares to 4,554,412,915 shares following the placement of 297,300,000 new shares at a price of HK$0.049 per share[71]. - The Company approved a share consolidation on 2 August 2023, consolidating every ten issued and unissued ordinary shares into one consolidated share, resulting in a total of 455,441,291 issued shares[77]. - As of December 31, 2023, the total number of issued shares was 455,441,291, with a par value of HKD 0.01 per share, reflecting an increase from 425,711,291 shares in the previous fiscal year after the share consolidation[80]. - The Company successfully placed a total of 29,730,000 new shares at a placing price of HK$0.49 on May 2, 2023, resulting in net proceeds of approximately HK$14.0 million[163]. - The Group aims to strengthen its financial position through effective use of capital raised from the Placing[171]. Research and Development - The Asian Integrated Cell Laboratory under HK Zhong Ji 1 is recognized as the world's leading autoimmune cell bank, indicating a strong position in the biotechnology sector[174]. - The company is focused on integrating leading resources for knee joint health globally, which includes cell testing, storage, and gene therapies[174]. - The company has a strategic focus on advanced biomedical technology, with key executives having backgrounds in both business and healthcare sectors[180]. - The company is focused on innovation and scientific research, as evidenced by the involvement of leading experts in its management team[195].

智通财经APP讯，中基长寿科学(00767)公布，于2024年4月18日，公司的全资附属公司深圳市中基健康科学有限公司及公司间接非全资附属公司四川中基冠德生物科技有限公司与四川中农云起航数据科技集团有限公司订立合资协议，拟在中华人民共和国成立一间合资公司。合资公司于成立时将由中基冠德拥有51%、中基健康拥有25%及中农云拥有24%的股权。合资公司将主要从事在中国开发高血压、糖尿病临床管控新途径A+的微创技术、间质技术的应用，以及相关生物制品贸易的业务。 合资公司的初始注册资本为人民币200万元，将由中基冠德、中基健康及中农云按彼等各自于合资公司的权益比例出资。出资款将主要用作合资公司的营运资金。该集团将以其内部资源为其资本承担提供资金。 据悉，中农云是中华人民共和国农业农村部的全资附属公司蓝田投资总公司旗下的控股公司，注册资金为5000万元人民币，是多元化大型国有企业，业务范围涵盖：乡村振兴、林业碳汇、水利水电、应急领域、城市更新、文旅康养、医疗投资、产业投资等。 公告称，该集团主要透过其附属公司中基健康从事提供健康咨询及医疗产品贸易的业务，及中基冠德提供生物医药产品贸易的业务。董事会认为长寿生物制品及生物科 ...

Financial Performance - For the fiscal year ending December 31, 2023, the group's revenue decreased by 27.5% to HKD 65.0 million, compared to HKD 89.7 million in the fiscal year 2022[5]. - The group's gross profit for the fiscal year 2023 decreased by 32.9% to HKD 56.3 million, down from HKD 83.8 million in the previous year[5]. - The group's profit after tax increased by 259.9% to HKD 2.5 million for the fiscal year 2023, compared to HKD 0.7 million in fiscal year 2022[5]. - The total comprehensive loss for the fiscal year 2023 amounted to HKD 4.95 million, compared to a loss of HKD 69.61 million in fiscal year 2022[8]. - The adjusted profit before tax for the year ended December 31, 2023, was HKD 4,745,000, compared to HKD 9,323,000 in 2022, indicating a decrease of about 49.1%[22][24]. - The company reported a net profit of HKD 2,313,000 for 2023, compared to a net loss of HKD 904,000 in 2022[40]. - The annual profit for fiscal year 2023 was approximately HKD 2,523,000, compared to a profit of HKD 701,000 in fiscal year 2022[54]. Assets and Liabilities - The group's net assets increased by 2.3% to HKD 430.5 million, up from HKD 420.8 million in the previous year[5]. - The group's total assets less current liabilities stood at HKD 435.9 million, compared to HKD 421.5 million in fiscal year 2022[10]. - The total assets as of December 31, 2023, amounted to HKD 509,254,000, an increase from HKD 484,839,000 in 2022, reflecting a growth of approximately 5.0%[26]. - The total liabilities as of December 31, 2023, were HKD 78,789,000, up from HKD 63,990,000 in 2022, which is an increase of about 23.1%[26]. - As of December 31, 2023, the group's net current assets amounted to approximately HKD 250,127,000, an increase from HKD 246,217,000 in the fiscal year 2022[67]. - The group had cash and cash equivalents of approximately HKD 81,075,000 as of December 31, 2023, compared to HKD 60,069,000 in the fiscal year 2022, reflecting a significant increase[67]. Earnings Per Share - The group's basic and diluted earnings per share for fiscal year 2023 were HKD 0.15, compared to a loss of HKD 0.06 per share in the previous year[7]. - Basic and diluted earnings per share for 2023 were HKD 0.00149, compared to a loss per share of HKD 0.0006 in 2022[40]. Dividends - The board of directors did not recommend a final dividend for the fiscal year 2023, consistent with the previous year[5]. - The company did not declare or recommend any dividends for 2023, consistent with 2022[39]. - No dividends were proposed for the fiscal year 2023, consistent with the previous fiscal year[90]. Segment Performance - The company reported a segment loss of HKD 24,016,000 in the longevity science business for the year ended December 31, 2023, compared to a profit of HKD 8,953,000 in 2022[22][24]. - The longevity science segment generated revenue of approximately HKD 31,326,000, down from HKD 43,920,000 in fiscal year 2022, with a segment loss of HKD 24,016,000[57]. - The lending and financial consulting segment recorded revenue of approximately HKD 33,663,000, a decrease from HKD 45,748,000 in fiscal year 2022, with a segment profit of HKD 25,354,000[61]. Cash Flow and Financial Costs - The group's cash and cash equivalents increased to HKD 81.1 million in fiscal year 2023, up from HKD 60.1 million in the previous year[10]. - The company's financial cost for the year ended December 31, 2023, was HKD (1,936,000), compared to HKD (417,000) in 2022, indicating an increase in financial costs[22][24]. Compliance and Governance - The audit committee, consisting of three independent non-executive directors, has reviewed and approved the consolidated financial statements for the fiscal year 2023, ensuring compliance with applicable accounting standards and regulations[97]. - The company has adopted the standard code of conduct for securities trading by directors, confirming compliance throughout the year[96]. - The company is committed to enhancing its internal control systems to prevent future delays in financial reporting as per listing rules[93]. - The risk management committee has monitored the company's adherence to risk management and internal control guidelines[94]. - The chairman of the board, Yan Li, confirmed the board's commitment to overseeing the effectiveness of risk management and internal control systems[101]. Future Plans and Strategies - The company aims to achieve global leadership in the sales revenue of lipid-lowering biological products by 2024, with the competitive product ZJ1 VC being used in over 117 countries[47]. - The company plans to replicate its standardized longevity management services in 26 major cities globally, enhancing its brand image among high-net-worth individuals[49]. - The company plans to continue expanding its longevity science business and may consider forming joint ventures with strategic partners to maximize shareholder returns[83]. - A joint venture agreement was signed on February 26, 2024, to establish a company in China focused on the trade of biopharmaceutical products, with the group holding a 51% stake[88].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中 基 長 壽 科 學 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：767） 有關二零二二年全年╱二零二三年中期業績及 報告之澄清及補充公告 茲提述中基長壽科學集團有限公司（「本公司」）日期為二零二三年四月十九日之截至 二零二二年十二月三十一日止年度之全年業績公告（「二零二二年全年業績公告」）； 本公司於二零二三年四月二十八日刊發之截至二零二二年十二月三十一日止年度之 年報（「二零二二年年報」）；本公司日期為二零二三年八月二十三日之截至二零二三 年六月三十日止六個月之中期業績公告（「二零二三年中期業績公告」）及本公司於二 零二三年九月二十二日刊發之截至二零二三年六月三十日止六個月之中期報告（「二 零二三年中期報告」）。除另有說明外，本公告所用詞彙與二零二二年全年業績公告 及二零二二年年報以及二零二 ...

Dividend and Financial Performance - The Company did not declare an interim dividend for the six months ended 30 June 2023, consistent with the previous year[10]. - For the six months ended June 30, 2023, the Group recorded total revenue of HK$29,911,000, a decrease from HK$33,054,000 in the same period of 2022[36]. - The Group reported a profit for the period of HK$1,938,000, down from HK$6,437,000 in the prior year[36]. - The basic and diluted earnings per share were HK$0.01, compared to HK$0.04 in the same period of 2022[37]. - Profit for the period was HK$1,938,000, down 69.9% from HK$6,437,000 in the prior year[39]. - The Company reported revenue of HK$29,911,000, a decrease of approximately 9.5% compared to HK$33,054,000 for the same period in 2022[169]. - Gross profit for the same period was HK$26,487,000, down from HK$29,108,000, reflecting a decline of about 9.0%[169]. - Profit before tax for the period was HK$5,312,000, a decrease of approximately 13.7% from HK$6,152,000 in the prior year[169]. - The profit for the period attributable to owners of the Company was HK$1,782,000, down from HK$6,273,000, representing a decline of approximately 71.6%[169]. - The Company incurred selling and distribution expenses of HK$11,959,000, significantly higher than HK$1,258,000 in the previous year, indicating an increase of approximately 848.5%[169]. - Administrative expenses rose to HK$26,937,000 from HK$21,467,000, marking an increase of about 25.4%[169]. - Other comprehensive loss for the period totaled HK$80,621,000, compared to HK$28,721,000 in the previous year, reflecting a significant increase[171]. - Total comprehensive loss for the period attributable to owners of the Company was HK$77,226,000, up from HK$21,825,000 year-over-year[171]. Business Operations and Revenue Sources - The existing Money Lending & Financial Advisory Business has shown steady recovery growth despite challenges from COVID-19 restrictions in major cities[16]. - The Company operates its money lending business through two models: the "Strategic Partners Model" and the "Corporate and Personal Borrowers Model"[12]. - The Company’s strategic partners include China Foreign Economy and Trade Trust Co. Ltd, Shenzhen Fanhua Joint Investment Group Co. Ltd, and Chongqing Haier[12]. - The Company’s loan assets are primarily in the form of residential loans managed through strategic partners, with a focus on home mortgage products[17]. - The Company’s financial advisory business continues to adapt to the evolving market conditions post-P2P loan transition[16]. - The Group's principal activities include longevity science, money lending, financial advisory, securities investments, and property investment[187]. - The longevity science business is expected to become a key revenue growth driver for the Group, supported by a network of 2,000 pharmacy outlets across various regions in China[53]. - The Group's financial performance reflects a significant shift in revenue sources, particularly in diagnostic services[199]. Longevity Science Business - The Company is focused on expanding its longevity science business alongside its financial services[11]. - The Longevity Science Business contributed revenue of HK$11,868,000 but incurred a segment loss of HK$13,283,000[36]. - The longevity science business generated revenue of approximately HK$11,868,000, a decline of 33.9% from HK$17,953,000 in the same period last year, with a segmental loss of approximately HK$13,283,000 compared to a profit of HK$6,989,000 in 2022[42][44]. - Revenue from diagnostic consultation and medical testing was approximately HK$9,517,000, up 190.5% from HK$3,273,000 in the prior year[42][44]. - Sales of longevity biological products fell to approximately HK$2,351,000, a decrease of 84.0% from HK$14,680,000 in the same period last year due to customs clearance delays[43][45]. - The Group's strategy includes diversifying into the longevity medical health business, offering various advanced medical tests and treatments[27]. - The Group has strengthened its R&D capabilities by appointing Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist[47][49]. - The Group is developing its flagship NMN product "ZJ1" and other longevity biological products in California, with the R&D progress of "ZJ1" reaching the seventh generation[48][50]. - The Group plans to establish the "Internet + Healthcare" longevity system platform, Zhong Ji Longevity Cloud, leveraging its existing customer base and sales channels[48][50]. Market Environment and Challenges - The Company faces uncertainties due to PRC government policies offering mortgage repayment relief, impacting recovery actions[18]. - The Company’s operations are affected by the stringent market environment, particularly in property transactions in both PRC and Hong Kong[16]. - The PRC property market faced a slump, impacting the performance of home loans and secured loans in the Money Lending and Financial Advisory Business[34]. - The Group engaged a PRC law firm to expedite recovery actions on overdue loans, with progress reported by the end of July 2023[23]. Assets and Financial Position - The Group's consolidated net assets as of June 30, 2023, were HK$419,251,000, slightly down from HK$420,849,000 at the end of 2022[37]. - The Group's net asset value as of June 30, 2023, was HK$419,251,000, slightly down from HK$420,849,000 as of December 31, 2022[40]. - As of June 30, 2023, the Group recorded net current assets of approximately HK$231,394,000, a decrease from HK$246,217,000 as of December 31, 2022[85]. - The Group's cash and bank balances were approximately HK$58,733,000 as of June 30, 2023, down from HK$60,069,000 as of December 31, 2022[85]. - The total number of issued ordinary shares increased to 4,554,412,915 as of June 30, 2023, compared to 4,257,112,915 as of December 31, 2022[86]. - The gearing ratio of the Group was approximately 2.1% as of June 30, 2023, down from 2.4% as of December 31, 2022[105]. - The Group did not have any capital commitment as of June 30, 2023, consistent with the position as of December 31, 2022[107]. - The Group has not implemented any foreign currency hedging policy but is continuously monitoring foreign exchange exposure due to fluctuations in Renminbi[106]. - The Group had no material contingent liability as of June 30, 2023, the same as December 31, 2022[108]. Shareholding and Corporate Governance - The company continues to monitor and comply with the relevant regulations regarding shareholdings and interests[119]. - The total number of shares held by Mr. Yan Li, including convertible notes, represents approximately 212.79% of the total issued shares as of June 30, 2023[117][118]. - The company had no disclosed interests or short positions from directors or chief executives as of June 30, 2023[119][122]. - The company recorded no significant changes in substantial shareholders' interests as of June 30, 2023[120][123]. - The Company has complied with the Corporate Governance Code during the six months ended June 30, 2023[156]. Legal Matters - An unlawful leasehold interest transfer was discovered, involving Keen State Global Saipan, which was executed without the knowledge or authority of the Group[76]. - Internal inquiries confirmed that no staff or directors of the Group authorized the unlawful lease assignment, which is being challenged legally[79]. - The Group has authorized legal actions to invalidate the forged lease assignment and recover possession of the leasehold interest[81].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中 基 長 壽 科 學 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：767） 截至二零二三年六月三十日止六個月 留意人名： 中期業績公告 中基長壽科學集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 曹衆女士係要用「衆」 附屬公司（統稱「本集團」）截至二零二三年六月三十日止六個月之未經審核簡明綜合中期 業績連同二零二二年同期之比較數字如下： 不是「眾」 ...

Financial Performance - In 2022, the company reported revenue of HK$89,668,000, an increase of 46.7% from HK$61,119,000 in 2021[10] - The company experienced a loss attributable to owners of HK$904,000 in 2022, compared to a profit of HK$6,055,000 in 2021[10] - As of December 31, 2022, total shareholders' equity was HK$420,849,000, down from HK$470,718,000 in 2021, representing a decrease of 10.5%[13] - The basic and diluted loss per share was approximately HK$0.01, a decrease from earnings per share of HK$0.04 in 2021[53][56] - For the year ended December 31, 2022, the Group recorded total revenue of approximately HK$89,668,000, an increase of 46.7% from HK$61,119,000 in 2021[52][55] - The longevity science business contributed revenue of approximately HK$43,920,000, up 96.0% from HK$22,446,000 in 2021, with a segment profit of approximately HK$8,953,000, compared to HK$3,500,000 in the previous year[58][61] - The Money Lending and Financial Advisory Business generated static revenue of approximately HK$45,748,000, with a segment profit of approximately HK$30,913,000[52][55] - For the year ended December 31, 2022, the money lending segment recorded revenue of approximately HK$45,748,000, up from HK$38,660,000 in 2021, and a profit of approximately HK$30,913,000, compared to HK$26,872,000 in 2021[72][74] Business Development - The company developed four longevity biological products in the US, all receiving the highest global standard of certification[16] - Strategic sales partnerships were formed with Sinopharm Group, Naber Pharmacy, Hong Kong Mannings Pharmacy, and Wing Wah Pharmacy[16] - The company has established a layout of Research & Development and production in the US, with services in Hong Kong and Japan, and marketing clients in China[16] - The company aims to build a membership-based international longevity management organization, providing advanced medical services in Hong Kong, Shenzhen, Los Angeles, and Tokyo[23] - The company is focused on optimizing its industrial and product chains to ensure healthy and sustainable development, despite ongoing economic uncertainties[21][24] - The Group's longevity science business is focusing on strengthening in-house R&D and production capabilities, including the appointment of Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist[60][62] - The Group has commenced the development and production of its flagship NMN product "ZJ1" and other longevity biological products in California, USA[64] - The Group aims to establish the "Internet + Healthcare" longevity system platform — Zhong Ji Longevity Cloud[64] Challenges and Regulatory Issues - The company faced trading suspension from January to late July 2022 due to regulatory challenges[14] - In 2022, the company faced challenges including the suspension of share trading from January to late July and the impact of the COVID-19 pandemic, yet it maintained a focus on steady progress and development[17] - The company successfully appealed to the Listing Review Committee in July 2022, leading to the resumption of share trading, which is expected to provide a fair development environment for sustainable growth[17][27] Corporate Governance and Management - The company aims to enhance corporate governance and business operations for sustainable development[14] - The company plans to continue enhancing its corporate governance and operational standards to protect shareholder interests and ensure sustainable growth[24] - The board includes independent non-executive directors with extensive experience in finance, corporate management, and medical fields[149][150][151][152] - The company’s governance structure includes multiple committees to oversee audit, remuneration, risk management, and nominations[149][150][151][152] - The Group is committed to enhancing its environmental, social, and governance (ESG) practices, with a report expected to be published by the end of April 2023[167] Strategic Partnerships - The company has established a strategic collaboration with Thermo Fisher Scientific, valued at over HK$20,000 billion, to enhance its longevity management services targeting high net worth individuals[19] - The company has established a strategic partnership with Stanford University's Center for Translational Medicine to develop advanced medical services in Hong Kong[19] - The Group has established a strategic partnership with Thermo Fisher Scientific, which will provide the latest life science technology and solutions to enhance the Group's R&D capabilities in longevity science[65][68] Investment and Financial Position - As of December 31, 2022, the consolidated net assets of the Group were approximately HK$420,849,000, down from HK$470,718,000 in 2021[53][56] - The Group recorded a net fair value loss of approximately HK$11,366,000 on listed securities investments, compared to a loss of HK$10,795,000 in 2021[81] - The Group's investment in 271,345,000 shares of Imperial Pacific International Holdings Limited amounted to an investment cost of approximately HK$76,490,000, representing about 3.8% of Imperial Pacific's issued share capital[82] - The fair value of the shares of Imperial Pacific held by the Group was HK$24,145,000 as of December 31, 2022, which accounted for 46.2% of the Group's total investment in listed securities and approximately 4.7% of the Group's total assets[82] - The Group commenced property investment business in 2021, but the properties remained vacant and did not generate any revenue in 2022 due to the pandemic[88] - The Group incurred miscellaneous expenses related to the properties during 2022 and plans to find suitable tenants or dispose of the properties for capital appreciation[88] Management Team - Mr. Yan Li has over 8 years of experience in advanced medical and biological technology management[133] - Mr. Yan Yifan joined the company as CEO in April 2022, previously serving as general manager of Mailyard Health Group[134] - Mr. Li Xiaoshuang, an executive director, has extensive experience in business operation and corporate management after retiring from gymnastics[138] - Ms. Cao Xie Qiong, an executive director, has a background in advanced biomedical technology and has held leadership roles in the food and beverage industry[139] - Dr. He Yiwu, a non-executive director, has a PhD from Boston University and extensive experience in innovation and pharmaceutical sectors[143] - Mr. Lyu Changsheng, an independent non-executive director, has over 20 years of experience in investment consulting and corporate development[144] - Mr. Lee See Barry, an independent non-executive director, has over 30 years of experience in audit, accounting, and financial management[145]